secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K/A
Filed at:   2022-01-14T23:59:59+00:00
Accession:  0001447362-22-000016
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences acquires Cernostics for up to $30M upfront plus $50M earnout
-------------------------------------------------------------------------------

- Up-front consideration $30M (cash or cash/stock mix); earnouts up to $50M based on 2022 commercial milestones.
- Cernostics 9M2021 revenue $469K, net loss $2.8M; 2020 revenue $141K, net loss $2.6M.
- Cernostics' TissueCypher Barrett's Esophagus Assay added to Castle's diagnostics portfolio.
- Transaction closed December 2021; amendment files required financial statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000016/0001447362-22-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000016/cstl-20211202.htm
  HTML page:      https://secwatch.observer/filing/0001447362-22-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer